Aperio Group LLC increased its position in Qiagen NV (NASDAQ:QGEN) by 13.5% during the third quarter, Holdings Channel reports. The institutional investor owned 184,966 shares of the company’s stock after buying an additional 21,973 shares during the period. Aperio Group LLC’s holdings in Qiagen NV were worth $5,075,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of QGEN. Fuller & Thaler Asset Management Inc. acquired a new position in shares of Qiagen NV during the second quarter valued at about $116,000. First Mercantile Trust Co. purchased a new stake in Qiagen NV during the second quarter valued at approximately $126,000. SG Americas Securities LLC raised its stake in Qiagen NV by 9.9% in the second quarter. SG Americas Securities LLC now owns 6,977 shares of the company’s stock valued at $152,000 after buying an additional 629 shares in the last quarter. Societe Generale purchased a new stake in Qiagen NV during the second quarter valued at approximately $152,000. Finally, Stephens Inc. AR raised its stake in Qiagen NV by 14.5% in the second quarter. Stephens Inc. AR now owns 8,255 shares of the company’s stock valued at $180,000 after buying an additional 1,043 shares in the last quarter. 57.33% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Qiagen NV (NASDAQ:QGEN)

Shares of Qiagen NV (NASDAQ:QGEN) traded up 1.55% during trading on Tuesday, reaching $27.52. 788,076 shares of the company’s stock were exchanged. The stock has a 50 day moving average price of $26.50 and a 200-day moving average price of $24.83. Qiagen NV has a 52 week low of $19.94 and a 52 week high of $28.50. The stock has a market capitalization of $6.45 billion, a price-to-earnings ratio of 55.04 and a beta of 1.07.

Qiagen NV (NASDAQ:QGEN) last posted its earnings results on Wednesday, November 2nd. The company reported $0.29 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.28 by $0.01. Qiagen NV had a net margin of 8.96% and a return on equity of 9.34%. The firm earned $338.70 million during the quarter, compared to the consensus estimate of $335.46 million. During the same period last year, the firm posted $0.27 EPS. The firm’s revenue for the quarter was up 7.7% on a year-over-year basis. Analysts predict that Qiagen NV will post $1.03 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Financial Market News and is owned by of Financial Market News. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece can be accessed at http://www.financial-market-news.com/aperio-group-llc-raises-position-in-qiagen-nv-qgen/1208995/.

Several analysts have recently issued reports on QGEN shares. Commerzbank AG reiterated a “buy” rating on shares of Qiagen NV in a research report on Wednesday, November 16th. JPMorgan Chase & Co. reiterated a “hold” rating and issued a $27.00 target price on shares of Qiagen NV in a research report on Thursday, November 3rd. Barclays PLC reiterated a “buy” rating and issued a $28.00 target price on shares of Qiagen NV in a research report on Thursday, November 3rd. Bank of America Corp. upgraded shares of Qiagen NV from an “underperform” rating to a “neutral” rating in a research report on Thursday, November 3rd. Finally, Zacks Investment Research lowered shares of Qiagen NV from a “buy” rating to a “hold” rating in a research report on Wednesday, October 19th. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $26.60.

Qiagen NV Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems.

5 Day Chart for NASDAQ:QGEN

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen NV (NASDAQ:QGEN).

Receive News & Ratings for Qiagen NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen NV and related companies with MarketBeat.com's FREE daily email newsletter.